Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Update

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) saw a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 20,600 shares, an increase of 174.7% from the November 15th total of 7,500 shares. Based on an average daily trading volume, of 44,000 shares, the short-interest ratio is currently 0.5 days.

Institutional Trading of Global X Genomics & Biotechnology ETF

A number of hedge funds have recently bought and sold shares of GNOM. One Capital Management LLC raised its stake in shares of Global X Genomics & Biotechnology ETF by 22.1% in the second quarter. One Capital Management LLC now owns 680,311 shares of the company’s stock valued at $7,102,000 after purchasing an additional 123,339 shares in the last quarter. Flow Traders U.S. LLC bought a new position in shares of Global X Genomics & Biotechnology ETF during the 3rd quarter worth about $936,000. Oppenheimer Asset Management Inc. boosted its position in shares of Global X Genomics & Biotechnology ETF by 10.2% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 67,712 shares of the company’s stock valued at $707,000 after acquiring an additional 6,260 shares in the last quarter. Corrado Advisors LLC increased its stake in Global X Genomics & Biotechnology ETF by 3.0% in the third quarter. Corrado Advisors LLC now owns 64,224 shares of the company’s stock valued at $723,000 after acquiring an additional 1,894 shares during the period. Finally, Sanctuary Advisors LLC acquired a new position in Global X Genomics & Biotechnology ETF in the second quarter worth about $590,000. 56.95% of the stock is owned by institutional investors.

Global X Genomics & Biotechnology ETF Stock Down 2.0 %

Shares of GNOM stock traded down $0.21 during trading hours on Thursday, reaching $10.44. 90,769 shares of the company’s stock were exchanged, compared to its average volume of 57,332. The business has a fifty day moving average price of $10.62 and a 200-day moving average price of $10.85. The stock has a market capitalization of $76.32 million, a P/E ratio of -4.50 and a beta of 1.03. Global X Genomics & Biotechnology ETF has a fifty-two week low of $9.52 and a fifty-two week high of $12.53.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.